Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Barchart Technical Opinion STRONG BUY
The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.
Long term indicators fully support a continuation of the trend.
https://www.barchart.com/stocks/quotes/FDIT/overview
I did some research based on one of the people posting here regarding Ray Firth. He was never a board member of another public company and has not sold shares in years in FDIT. So please note that the claims in red above and other posts are simply opinions they are debunked by the facts.
Breakout Alert: 9-21-2020
Huge Breakthrough For GWHP Receives "FDA" Acknowledgement
Letter for Its "Antigen Rapid Test" For COVID-19!
Dear Fellow Trader,
Immediately turn your attention to Global WholeHealth Partners (GWHP)
More Bombshell News Dropped!
GWHP announced they've received FDA Acknowledgement Letter for the Global Antigen CoViD19 SARS2 Rapid-Test!
GWHP Rapid Diagnostic Testing (RDT) Whole Blood, Serum /Plasma Can Detect Between 15 -20 Minutes, Which Predict Diseases Ahead Of Its Industry Competitors.
The Antigen test is a "Game Changer" because the test reveals if a person is "currently" infected with a pathogen such as the SARS-CoV-2 virus. Once the infection has gone, the antigen disappears.
Unlike nucleic acid-based tests such as PCR, which detect the presence of genetic material, antigen tests detect proteins or glycans, such as the spike proteins found on the surface of the SARS-CoV-2 virus.
Global WholeHealth Partners (GWHP) Announces It Had Submitted an Emergency
Use Authorization (EUA) Application # PEUA201789 Date 09/14/2020: for the Global Antigen CoViD19 SARS2 Rapid Test as Mentioned in the 8K Filing on 09/15/20
SAN CLEMENTE, CA, Sept. 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Global WholeHealth Partners Corp. (GWHP) announces it had submitted an Emergency Use Authorization (EUA) Application Submission Number: PEUA201789 Acknowledgement Letter date 09/14/2020: for the Global Antigen CoViD19 SARS2 Rapid Test as mentioned in the 8K filing dated September 15th, 2020.
Global WholeHealth Partners Corp. (OTC MKTS: GWHP) announced today that an application for Emergency Use Authorization (EUA) under the PreEUA is under review at the U.S. Food and Drug Administration (FDA) for Global Antigen CoViD19 SARS2 Rapid Test.
Global WholeHealth Partners Corp. offers cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR test that detects in 1 1/2 hours and the Rapid Diagnostic Testing (RDT) Whole Blood, Serum /Plasma that can detect between 15 -20 minutes, which predict diseases ahead of its industry competitors.
Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp, said, “The Company’s goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Nasal Swab Influenza A & B, and Throat Swab Strep A, Urine and Saliva Drug Testing, Whole Blood Mononucleosis, H. Pylori, FOB, and several other tests.”
For international testing, which is not sold in the USA, but has a Certificate of Exportability by the FDA Certificate No. 2260-11-2019, are tests like Rapid Ebola, Rapid Dengue Fever Antibody and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests. The rapid antibody test allows results to be available in 15 minutes or less. The easy to use assay develops three clear lines that confirm the assay validity and the qualitative detection and differentiation of IgM and IgG antibodies to the SARS-CoV-2 virus.
Right now, under the FDA guidelines, GWHP is selling the Covid-19 rt-qPCR Test to high complexity labs or medical institutions that qualify under the FDA guidelines as Global had partnered with 1 Drop, which has received its FDA EUA Authorization. Global is also selling the IgG/IgM Antibody Rapid Test for Covid-19 as Global has partnered with Healgen which has received its FDA EUA Authorization.
About Global WholeHealth Partners Corp.:
Global WholeHealth Partners Corp's Made In the USA Covid-19 Rapid Test Kit are manufactured in sunny San Diego, California and are suitable for the qualitative detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood within 15 minutes.
By so doing, GWHP has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. Our vision is to lead the industry in infectious disease diagnostics and provide molecular solutions that lessen the time to diagnose medical results and empower healthcare professionals.
The Bottom Line...
If you haven't taken a look at this stock yet, this is your chance. Put GWHP on your screen.
My track record for covid-19 related stock trades has dished out 3,545% gains with my previous covid-19 diagnostics stock CODX which ran from my alert price of $.85 to $30 following a favorable response to its EUA earlier this year, reaching a peak valuation of 20x next year's EPS.
Using A Similar Multiple On GWHP, Research Analyst Rob Goldman
Projects GWHP Could Reach $11.20 Next Year
(Representing an approx. 600% upside potential)
Follow Me Closely Here, if you missed my previous stock pick run from $.85 to $30, here is your second chance with my newest COVID-19 diagnostics stock GWHP.
Here is a few more of my previous covid-19 related stock trades:
• (Axsome Therapeutics): Profile price pre-mkt $5.00 1/7/19 – High $109.94 12/30/19 (2,098% Gains)
• (Applied DNA Sciences): Profile price pre-mkt $4.80 4/15 – High $16.39 5/14 (241% Gains)
• (Sorrento Therapeutics): Profile price pre-mkt $4.30 5/15 – High $19.39 8/10 (350% Gains)
You must take this particular pick very seriously, pay attention to the magnitude of their Bombshell "FDA" Acknowledgement Letter for Its "Antigen Rapid Test" For Covid-19.
I am urging all of my members to add GWHP to the top of their watch list right now, and be ready Monday morning at the opening bell!
BullRally
Trading Research Team
Findit, Inc. Owner of Findit.com Will Welcome TikTok and WeChat Members Due to Ban Starting Sunday September 20, 2020
https://www.accesswire.com/606709/Findit-Inc-Owner-of-Finditcom-Will-Welcome-TikTok-and-WeChat-Members-Due-to-Ban-Starting-Sunday-September-20-2020
FORM 8-K Filed have a read
GLOBAL WHOLEHEALTH PARTNERS CORP
FORM 8-K
(Current report filing)
Filed 09/15/20 for the Period Ending 09/14/20
Address 2227 AVENIDA OLIVA
SAN CLEMENTE, CA, 92673
Telephone (714) 392-4112
CIK 0001598308
Symbol GWHP
SIC Code 2835 - In Vitro and In Vivo Diagnostic Substances
Industry Healthcare Facilities & Services
Sector Healthcare
Fiscal Year 06/30
http://www.edgar-online.com
© Copyright 2020, EDGAR Online, a division of Donnelley Financial Solutions. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, a division of Donnelley Financial Solutions, Terms of Use.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 14, 2020
GLOBAL WHOLEHEALTH PARTNERS CORPORATION
(Exact name of registrant as specified in its charter)
Nevada 000-56035 46-2316220
(State or other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer
Identification No.)
2227 Avenida Oliva
San Clemente, CA 92673
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (714) 392-9752
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.?
Section 8 - Other Events
Item 8.01 Other Events.
On September 14, 2020, Global Wholehealth Partners Corporation (the “Company”) received an Acknowledgment Letter (the “Letter”) from
the U.S. Food and Drug Administration (the “FDA”) that the Center for Devices and Radiological Health of the FDA has received the
Company’s Global Rapid Antigen Test test application submitted by Charles Strongo, the Company’s Chief Executive Officer. The
Company’s submission has been assigned the unique document control number PEUA201789.
A copy of the Letter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Section 9 – Financial Statement and Exhibits
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Document Location
99.1 FDA Letter received September 14, 2020. Filed Herewith
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
GLOBAL WHOLEHEALTH PARTNERS CORPORATION
(Registrant)
Date: September 14, 2020 By: /s/ Charles Strongo
Charles Strongo
Chief Executive Officer
https://www.otcmarkets.com/filing/conv_pdf?id=14390618&guid=45o6UF7exZFK93h
Currently up 20%
Mondays Profile GWHP The Next Major COVID-19 Diagnostics Company
With Extensive Patent Portfolio and $11 Price Target
Dear Fellow Trader,
This $1.50/share medical diagnostics company is set to emerge as a major provider of COVID-19 diagnostics test kits, an estimated $5.1B market.
This company has filed an Emergency Use Application (EUA) with the FDA for its rapid anti-body test with a response pending.
Additionally, this $1.50/share stock recently received analyst coverage, and got a staggering $11.20/share 12-month price target! (Representing an approx. 600%+ upside potential)
In studies performed earlier this year, their covid-19 rapid test produced such an enviable accuracy rate that the Department of the U.S. Navy placed an order for 1000 kits.
Go ahead, see the analyst report >> right here <<
https://www.goldmanresearch.com/202008281284/Opportunity-Research/the-next-major-covid-19-player.html
The test’s accuracy was found to be over 97%, with limited false positives, a major differentiator.
Once approved, the kit has significant advantages over existing tests in use today. These include low cost of $25/test, rapid point-of-care (PoC) results in 15 minutes, which removes the main bottleneck to testing processes, and is made in the USA.
Look here for the full analyst report with $11.20/share price target
Happy Trading!!
Your StockEgg Editor
https://www.goldmanresearch.com/202008281284/Opportunity-Research/the-next-major-covid-19-player.html
The Barchart Technical Opinion Rating Upgraded
FDIT Bullish 100% BUY Opinion
Dear Fellow Trader,
Immediately turn your attention to Findit (FDIT)
This is my next stock ready to potentially move in a big way, here's why...
Imagining one year ago that TikTok would shake the status quo of social media would have been impossible.
Yet the platform has been operating since 2016. Tiktok took a few years to become global and to become a serious competitor to the current giants.
I was doing my usual research on trends about social media when I saw an unusual spike in one keyword in particular which I pulled up: Findit (FDIT)
Initially launched a couple of years ago, the platform has only started to take off recently.
Why exactly, growing frustration with social networks and their censorship. Other social networks have incredibly unpopular algorithms combined with a growing number of data leaks on other platforms, may have been the catalyst.
Findit App is a social network that says it has no spyware, targeting, political bias, or news feed manipulation and No Censorship.
In other words, Findit (FDIT) bills itself as the “Anti” Censorship Social network and is Pro First Amendment.
Findit App Fill The Void,
TikTok’s Ban Sparks Findit (FDIT) Rise
With over 800 million active users worldwide, TikTok’s growth since its $1 billion rebrand of Music.ly in 2018 — a number thought to have been bolstered by the coronavirus pandemic — has been nothing short of exponential.
The short-form video app has a huge user base in the U.S., which could now be in jeopardy after a handful of comments from Secretary of State Mike Pompeo, who said he is “looking into” a ban on the platform and other Chinese-made apps following scrutiny over security.
The comments come on the heels of India’s recent ban; a huge blow to the social media app given that India is TikTok’s biggest market for new downloads, as well as access to one of the world’s fastest growing tech markets. The ban has meant the loss of approximately 120 million users from the platform, and has seen view counts and “likes” fall across all regions as a result.
TikTok’s thousands of influencers are somewhat concerned, with many opting to form contingency plans in case the worst should occur. Many could be shifting their efforts over to Findit (FDIT).
The recent controversy around TikTok is a huge boon for Findit (FDIT), who sees a big rival in TikTok for social media supremacy, especially in the youth market.
Imagine what could happen if FDIT an open-source social media platform filled the void caused by the ban on Chinese apps.
As millions of users scout for new social media platform in the wake of the ban on 59 Chinese apps and growing privacy and security concerns on the US ones, an open-source and decentralized platform Findit (FDIT) which is touted as an antithesis to Facebook and Twitter, could be aiming big to fill the void?
Findit could provide millions of users left scrambling for a new social media platform... so make sure you have it pulled up on your trading screen Tuesday morning at the opening bell!
As TikTok Faces Another Ban,
This Could Be Good News For FDIT Investors?
As TikToks woes continue, it could be good news for Findit (FDIT). TikTok, a Chinese video app, has become a major hit with teens and young adults. TikTok recorded over 730 million downloads in 2019, which makes it the world’s second-most downloaded app.
TikTok Bans would undoubtedly hobble what has become one of the fastest-growing social media businesses on the planet, with 800 million monthly active users worldwide, half of whom are under age 24.
In the meantime, the mere suggestion of a ban could prove a boon to one of TikToks rivals, Findit.
Findit'slaunch of the Right Now status update feed could be its answer to TikTok, which could be even worse for TikTok as their facing scrutiny from Washington.
The Right Now status update feed allows visitors to view posts from members on Findit and share them to other social networking sites and allows members to share the content they have created on Findit, such as their Right Now posts to their very own social networking accounts.
Right Now posts on Findit are unique when compared to posts on Twitter, Facebook, LinkedIn and Instagram!
What Makes A Findit Right
Now Post Unique?
The following pieces of content can be included in a single post - unlimited word count, pictures, video, an audio or music file, a link to another web page and a press release that has been submitted through Findit, can all be added in a single post!
As a result of having the option to include this vast amount of content verticals, each post can be incredibly relevant when Google crawls the Right Now page increasing the likelihood of a post getting indexed higher in search results. In addition to what, you can include in a post, unlike Facebook, Twitter, LinkedIn and Google, plus you can share your Findit Right Now posts to each of them which is very unique -- because the other social media platforms DO NOT allow you to share the posts done in their social media accounts to each of the other social media platforms.
As more people become aware of Findit (FDIT) and recognize they provide members a true starting point to build their brand when they create relevant posts that Google, Yahoo and Bing can index. Posts can be seamlessly shared up to 80 other social networking accounts either by the creator of the post or visitor to Findit.
Findit is focused on continuing to improve its platform, making it a place for people who want to have more control over the content they want seen on the web, indexed in search engines and shared to other social networking sites will join. Findit is for everyone: an individual, a business, churches, schools, sports teams, clubs and politicians.
Once a member experiences first hand a post that they create and share to their other social networking accounts and see it indexing in search engines, they become a believer. Findit does what it has been set up to do - provide members with social media content management platform.
Download Findit App Now
Findit (FDIT) is a Social Networking Content Management Platform that empowers members to get more out of their current social networking accounts.
One Of The Really Unique Features Findit Offers
Is Its Social Sharing Feature
Findit provides social sharing features that allow members of Findit as well as visitors using the App, to share Findit posts to Twitter, Instagram, Facebook, WhatsApp, via Email Address or a Text Message. Findit is an open-source and decentralized platform granting access to search engines to crawl and index your content so you can reach more people.
Use Findit to:
Post Right Now status updates
Post photos
Post videos
Drive Traffic
Control and build your brand
Browse photos
Share videos
Interact with posts by leaving comments or likes and share posts from Findit to Facebook, Twitter, Instagram, WhatsApp, text or email.
Share your life with multiple photos and video in a single post
Build your web footprint you want the world to see.
Wall Streets leading provider of market data to the global financial, media, and commodity industries issued FDIT a bullish 100% BUY Rating. Read below
The Barchart Technical Opinion Rating Issued
FDIT Bullish 100% BUY Opinion
The Barchart Technical Opinion rating is a 100% Strong Buy with a Average short term outlook on maintaining the current direction. Click here
Also, long term indicators fully support a continuation of the trend.
I strongly suggest you click here and read the technicals immediately to learn why FDIT could turn out to be another potential breakout gainer like some of my previous winners.
Multiple Breakout Catalysts Signaling
Breakout Gain Potential
It’s important to note, FDIT is no stranger to breakouts. For example, it was trading at a low of $.0310 on Aug 13th, it surged to a high of $.08 on Aug 24th for 158%% in gains, VIRTUALLY overnight:
On June 3rd, FDIT was trading at $.0156, it surged to a high of $.0999 on June 22nd for 540% in gains.
On May 21st FDIT was trading at $.0150, it surged to a high of $.086 on June 9th for 446% in gains.
I've been waiting patiently for the perfect timing for FDIT, and it appears the time could be now at its current level.
Now it's time to cash in on what I anticipate could be the company's next potential breakout.
So, without wasting any more time, pull up FDIT right now on your trading screen and be ready Tuesday morning when the clock strikes 9:30AM EST!
Sincerely,
Editor In Chief, OTCtipReporter Team
Image
OTC Tip Reporter
4417 13th St. Saint Cloud, FL 34769
Unsubscribe | Change Subscriber Options
https://www.otctipreporter.com/
Here is the link to Goldman Research Report target $11.00 on GWHP
https://www.goldmanresearch.com/202008281284/Opportunity-Research/the-next-major-covid-19-player.html
Barchart has it at a 100% Buy
Barchart Technical Opinion
STRONG BUY
The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.
Long term indicators fully support a continuation of the trend.
https://www.barchart.com/stocks/quotes/FDIT/overview
HRSR Capitalizes On The Booming $8 Billion Agarwood "Liquid Gold"
Market With Their Latest Acquisition
Dear Fellow Trader,
HRSR is a fresh new "IPO style" play that hasn't traded much at all until yesterday!
Our low-float, "IPO style" alert HRSR is just starting to create attention, as it starts to breakout in record volume… it shattered its ten-day average volume traded Tuesday, by trading more than thirty-five times higher than the ten-day average volume traded… it's important to note its ten-day average volume 300...
Take a look at Fridays trading action, you will notice zero trading volume, hence New “IPO-Style” Alert!
That being said, make sure you continue to keep a close eye on this highly volatile ticker.
Outside of the bullish technicals, HRSR is breaking new ground with their latest news release that they've decided to narrow down its focus on the global tea market and wellness industry. The global tea market is expected to rise to over $73 Billion by 2024 whilst the wellness industry is a trillion-dollar market and one of the world's largest and fastest-growing industries.
HRSR is confident that it can establish strong unique selling proposition in both the global tea and wellness industries. According to Mr. Yap, CEO of Horrison Resources, the team is working relentlessly to develop its uniquely crafted premium quality Agarwood tea, aims to benefit the physical health and mental wellbeing of all drinkers. The tea will contain finest hand-picked Agarwood leaves and go through the tea production process by way of traditional roasting.
HRSR is working with various industry experts to fine tune in-depth plans on product development, market testing and commercialization of the Agarwood tea whilst ensuring the products and processes are in strict compliance with all applicable laws and regulations. Meanwhile, the company confirms that the recently acquired Aquilaria trees are healthy and strong and shall continue to monitor the growth and health condition of the trees.
Here's a Snap Shot of News
Horrison Resources to Focus on Developing
Novel Agarwood Tea
HONG KONG, Aug. 31, 2020 /PRNewswire/ -- Upon conducting rigorous market potential and opportunities assessment, Horrison Resources (OTC: HRSR) has decided to narrow down its focus on the global tea market and wellness industry. The global tea market is expected to rise to over $73 billion dollars by 2024 whilst the wellness industry is a trillion-dollar market and one of the world's largest and fastest-growing industries.
Horrison Resources is confident that it can establish strong unique selling proposition in both the global tea and wellness industries. According to Mr. Yap, CEO of Horrison Resources, the team is working relentlessly to develop its uniquely crafted premium quality Agarwood tea, aims to benefit the physical health and mental wellbeing of all drinkers. The tea will contain finest handpicked Agarwood leaves and go through the tea production process by way of traditional roasting.
Agarwood has been lauded since the dawn of time as a gem in the rough. Besides wood, the leaves of the Agarwood are the second most lucrative use of Agarwood for nutraceutical, medicinal, and pharmaceutical applications. Agarwood leaves can be produced abundantly and in a sustainable manner. Apart from being consumed as beverages, Agarwood leaves are also processed into dietary supplements that purportedly act as anti-diabetic and anti-cancer agents. Countries like China, Japan, Taiwan and Hong Kong have been exporting Agarwood leaves and have mostly been using it as the prime ingredient in their herbal teas.
In this day and age, Agarwood tea can be produced not only as dried leaves, but in more sophisticated instant beverages all thanks to new and advanced technology developed by enthusiastic scientists and technologists.
Horrison Resources is working with various industry experts to fine tune in-depth plans on product development, market testing and commercialization of the Agarwood tea whilst ensuring the products and processes are in strict compliance with all applicable laws and regulations. Meanwhile, the company confirms that the recently acquired Aquilaria trees are healthy and strong and shall continue to monitor the growth and health condition of the trees.
For anyone that may have missed my email from earlier, I've included a copy of our alert below.
-------------------------------------------------------------------------------------------------------------
HRSR Capitalizes On The Booming $8 Billion Agarwood "Liquid Gold"
Market With Their Latest Acquisition
Dear Fellow Trader,
Immediately turn your attention to Horrison Resources Inc. (HRSR)
HRSR is my next stock that looks ready to move in a major way, so make sure you have it pulled up on your trading screen this morning at the opening bell!
About Horrison Resources Inc.
Horrison Resources Inc. is a company that engages in exploring various business, joint venture and partnership opportunities within the agriculture and timber industries which are in line with the company’s mission to green the earth and tackle climate crisis. The company is working tirelessly towards planting, developing, researching, harvesting, cultivating and growing plantations with focus on Aquilaria species across the Asia regions while conserving the nature habitat in a most sustainable and environmentally friendly manner possible. Horrison Resources serves customers in Hong Kong, Malaysia and Singapore.
HRSR is operating in a sector that is said to be valued at US $64 Billion by the end of 2029.
The success of their recent acquisition has us bullish on the company's future!
HRSR Capitalizes On The Booming $8 Billion Agarwood "Liquid Gold"
Market With Their Latest Acquisition
In May, HRSR announced the completion of their acquisition of 1,000 Aquilaria (also known as Agarwood) trees from Mr. Nee Seng, Yap as part of its effort to combine long term financial growth of the company and to tackle climate crisis.
Agarwood is a fragrant dark resinous wood which forms in the heartwood of Aquilaria spp. and Gyrinops spp. trees (large evergreens native to Southeast Asia) after they are infected by fungus. It is now rarely seen in such habitats and is now considered to be threatened with extinction worldwide.
Due To Its Extremely Limited Supply, Rarity And High Value, Agarwood Is
Commonly Referred To As "Liquid Gold" Or The "Scent of Heaven"
It is widely used as a raw material for fragrances, traditional medicine, cosmetics, religious purposes, art, and food ingredient. Agarwood is among the most commercially valuable plant species in the world.
One Of The World's Most Expensive Natural Commodities,
Selling For More Than US$50,000 A Kilogram
In an article published on Frontiers in Plant Science on July 16, 2019 (PMID: 31379890), it was reported that the price per kilogram of Agarwood can range from US$100 to US$100,000 depending on the quality and grades.
Oud oil distilled from the Agarwood chips is one of the world's most expensive natural commodities, selling for more than US$50,000 a kilogram.
Oud oil is a key skin care ingredient with many anti-inflammatory and anti-microbial properties. In addition, Oud oil is also used as a key ingredient by all the major international fragrances companies to portray their fragrances as luxury items and status symbols.
The increasing demand for organic cruelty-free cosmetics is a reason why approximately US$90MIL of Oud oil was exported into the United Kingdom and Europe in 2019.
It's important to note, the current global market for Agarwood is estimated to be in the range of US$6–8 million and is growing rapidly, displaying unlimited future business potential. According to Persistence Market Research, the Agarwood chips market is forecasted to reach nearly US$64 Billion by the end of 2029.
The CEO of Horrison Resources, Nee Seng, Yap (Tony Yap) explained that Agarwood is a green 'gold mine' of the future. The acquisition of Agarwood trees would deliver strong and steady long-term value and ultimate growth to the company and its shareholders.
The primary objectives of this acquisition are to generate income from the harvest of Agarwood trees, propagation of its benefits while conserving the Agarwood habitat in a sustainable and environmentally friendly manner, and to effectively offset the carbon footprint of our investors.
Timber investments such as Agarwood trees offer great hedge against inflation uncorrelated to either stocks or bonds thereby secure long-term value of the company's portfolio. Agarwood trees allow for flexibility of harvesting more when prices are high and less when prices are low which render Agarwood trees to continue grow independent of the pace of economic activity.
Mr. Tony Yap anticipates that the benefit from the acquisition will come not only from the price of the cut Agarwood, but from the growth of the Agarwood trees themselves. The products made of and from Agarwood are still rare which indicates Agarwood will not suffer from devaluation after long term storage. As a collectible commodity, Agarwood is able to maintain its value and has low decay rate.
The longer it is stored the more valuable it is. Each and every part of the tree, namely: leaf, flower, fruit, trunk, branch, skin and root, has its own value. Mr. Tony Yap is confident that the future market of Agarwood is immeasurable. Combine the aforementioned with skillful interventions of experienced managers and industry experts, the profitability and sustainability can be maximized.
Mr. Tony Yap is a seasoned business entrepreneur who possesses great experience, skill and knowledge in the Agarwood industry. He had spent years conducting extensive studies and investigation from all around the world in the subject matter. He serves as the Chairman of Agarwood Entrepreneur Malaysia Association (Non-Governmental Organization).
The company is hopeful that this initiative will bring about various environmental, economic and social benefits, and that Agarwood trees will be valuable asset that hopefully one day can lead to steady profits which may ultimately benefit all shareholders/investors. Green investments are on the rise both in popularity and the returns they offer. Aside from company's corporate social responsibility (CSR) to address climate change this acquisition can create perfect asset for long-term security and wealth building. The company will continue to explore opportunities in working towards making significant contribution to the global Agarwood plantation and industry.
Horrison Resources CEO Calls Agarwood
Acquisition A Success!
The Aquilaria trees are placed in a nursery facility situated in Penang, Malaysia to maintain their optimal condition and are well secured to prevent damage caused by illegal loggers or wild animals. Plantation managers and workers were hired to monitor the growth and health condition of the Aquilaria trees.
The CEO of Horrison Resources, Mr. Yap expressed his pleasure with the results from the acquisition of the Aquilaria trees thus far. The company is currently working on a comprehensive execution plan to materialize the commercialization of Agarwoood in all its form and by-products. With skillful interventions of experienced managers, industry experts and farming technology, Mr. Yap is confident that the acquired Aquilaria trees will deliver strong and steady long-term value and ultimate growth to the company and its shareholders.
Mr. Yap will seek an independent valuation and assessment of the Aquilaria trees. The valuation aims to provide shareholders with comfort and confidence in the company's future.
HRSR is operating in a sector that is said to be valued at US$64 Billion by the end of 2029.
The success of their recent acquisition has us bullish on the Company's future!
I am urging all of our members to add HRSR to the top of your watch list right now, and be ready this morning at the opening bell!
Sincerely,
Editor In Chief, OTCtipReporter Team
Image
OTC Tip Reporter
4417 13th St. Saint Cloud, FL 34769
Unsubscribe | Change Subscriber Options
CODX earlier this year was covered by OTC Tip Reporter early on. This Friday OTC Tip Reporter put out a newsletter on GWHP. Earlier in the day a report was published as well. CODX followers that found out about CODX via OTC Tip Reporter back in late 2019 or early 2020 GWHP is one they are now covering.
"GWHP peer Co-Diagnostics has enjoyed a major run-up in its shares following a favorable response to its EUA earlier this year, reaching a peak valuation of 20x next year's EPS. Using a similar multiple on our forecasts, we project GWHP could reach $11.20 next year, concluded Goldman."
https://finance.yahoo.com/news/goldman-small-cap-research-issues-120000066.html
Goldman Small Cap Research Issues New Research Report on Global WholeHealth Partners Corporation
"GWHP peer Co-Diagnostics has enjoyed a major run-up in its shares following a favorable response to its EUA earlier this year, reaching a peak valuation of 20x next year's EPS. Using a similar multiple on our forecasts, we project GWHP could reach $11.20 next year, concluded Goldman."
https://finance.yahoo.com/news/goldman-small-cap-research-issues-120000066.html
Barchart upgrades FDIT to 100% Buy- Doesn't get higher than that.
https://www.barchart.com/stocks/quotes/FDIT/opinion
Findit Inc (FDIT)
0.0568 -0.0057 (-9.12%) 08/26/20 [OTC US]
BARCHART OPINION for Wed, Aug 26th, 2020Tutorial Alerts Watch Help
Overall Average:
100% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.
Barchart Opinion INDICATOR
Opinion Strength & Direction
Composite Indicator
TrendSpotter
BUY
Short Term Indicators
20 Day Moving Average
BUY
20 - 50 Day MACD Oscillator
BUY
20 - 100 Day MACD Oscillator
BUY
20 - 200 Day MACD Oscillator
BUY
20 - Day Average Volume: 223,720 Average: 100% BUY
Medium Term Indicators
50 Day Moving Average
BUY
50 - 100 Day MACD Oscillator
BUY
50 - 150 Day MACD Oscillator
BUY
50 - 200 Day MACD Oscillator
BUY
50 - Day Average Volume: 272,902 Average: 100% BUY
Long Term Indicators
100 Day Moving Average
BUY
150 Day Moving Average
BUY
200 Day Moving Average
BUY
100 - 200 Day MACD Oscillator
BUY
100 - Day Average Volume: 235,578 Average: 100% BUY
Same Newsletter covered CODX very early on CLSK SRNE and DTSS.
Something to take a look at. Anyone can take a few minutes and look at the historical on each of these and when the coverage began.
Dear Fellow Trader,
I've been searching for another explosive low float breakout stock like your previous big picks, which went gangbusters running up 344%, 116%, 97%, 500%, 471% in Gains!
Take a look below at a few of our recent picks:
#1.) First Profiled Co-Diagnostics July 2nd at $.85 cents, it rallied to a 52-week high of $30.99 Monday Aug 3rd providing members with 3,545% in gains.
#2.) First Profiled CleanSpark May 5th premarket at approx. $1.53, it rocketed to a new 52-week high of $13.61 Tuesday Aug 11th providing members with 789% in gains.
#3.) First Profiled Sorrento Therapeutics May 15th, premarket at approx. $4.30, it exploded to a new 52-week high of $19.39 Monday Aug 10th, providing members with 350% in gains.
#4.) First Profiled Datasea April 1st at $2.21, it rocketed to a high of $6.24 Monday Aug 3rd, providing members with 182% in gains.
If you liked your picks above that gained a combined total of 4,866% in Gains, I believe you are going to love your NEXT Low Float Breakout Stock.... FDIT
Now Turn Your Complete Attention to FDIT
Our NEXT Focus Stock
Immediately turn your attention to Findit Inc. (FDIT)
This is my next stock ready to potentially move in a big way, here's why...
As TikTok faces another ban: could be good news for FDIT investors?
As TikToks woes continue, it could be good news for Findit, Inc. (FDIT). TikTok, a Chinese video app, has become a major hit with teens and young adults. TikTok recorded over 730 million downloads in 2019, which makes it the world’s second-most downloaded app.
TikTok Bans would undoubtedly hobble what has become one of the fastest-growing social media businesses on the planet, with 800 million monthly active users worldwide, half of whom are under age 24.
In the meantime, the mere suggestion of a ban could prove a boon to one of TikToks rivals, Findit (FDIT)!
Especially with TikTok ban which could leave a void for millions of users now looking for new social media platform.
TikToks Loss is FDIT Gain!
The Banning of TikTok Could Leave a
Void For Millions of Users!
FDIT is my next stock that looks ready to move in a major way, here’s why…
Imagine what could happened... FDIT an open-source social media platform wants to fill the void caused by the ban on Chinese apps.
As millions of users scout for new social media platform in the wake of the ban on 59 Chinese apps and growing privacy and security concerns on the US ones, an open-source and decentralized platform FDIT which is often touted as an antithesis to Facebook and Twitter, could be aiming big to fill the void?
FDIT could potentially provide millions of users left scrambling for a new social media content management platform... so make sure you have it pulled up on your trading screen Monday morning at the opening bell!
With FDIT launch of the Right Now status update feed could be its answer to TikTok, which could be even worse for TikTok as their facing scrutiny from Washington.
The Right Now status update feed allows visitors to view posts from members on Findit and share them to other social networking sites and allows members to share the content they have created on Findit, such as their Right Now posts to their very own social networking accounts.
Right Now posts on Findit are unique when compared to posts on Twitter, Facebook, LinkedIn and Instagram.
What Makes A Findit Right Now Post Unique?
The following pieces of content can be included in a single post: Unlimited word count, pictures, video, an audio or music file, a link to another web page and a press release that has been submitted through Findit, can all be added in a single post.
As a result of having the option to include this vast amount of content verticals, each post can be incredibly relevant when Google crawls the Right Now page increasing the likelihood of a post getting indexed higher in search results. In addition to what you can include in a post, unlike Facebook, Twitter, LinkedIn and Google +, you can share your Findit Right Now posts to each of them but they do not allow you to share the posts done in their social accounts to each of the others.
As more people become aware of Findit and recognize that Findit provides members a true starting point to build their brand when they create relevant posts that Google, Yahoo and Bing can index and that can be shared to other social networking accounts either by the creator of the post or visitor to Findit.
Findit is focused on continuing to improve its platform, making it a place for people who want to have more control over the content they want seen on the web, indexed in search engines and shared to other social networking sites will join. Findit is for everyone: an individual, a business, churches, schools, sports teams, clubs and politicians.
Once a member experiences first hand a post that they create and share to their other social networking accounts and see it indexing in search engines, they become a believer. Findit does what it has been set up to do - provide members with social media content management platform.
The Bottom Line...
FDIT is my next stock that looks ready to move in a major way, especially with TikTok ban which could leave a void for millions of users now looking for new social media platform.
FDIT could potentially provide millions of users left scrambling for a new social media content management platform... so make sure you have it pulled up on your trading screen Monday morning at the opening bell!
So, without wasting any more time, don't delay and pull up FDIT on your trading screen for today before you miss out on another potential winner, with tremendous upside potential.
I am urging all of our subscribers to add FDIT to the top of their watch list right now, and be ready Monday morning at the opening bell!
Sincerely,
Editor In Chief, OTCtipReporter Team
Findit, Inc. Retains BF Borgers CPA PC Certified Public Accountants to Complete Audit for S1 Filing
https://finance.yahoo.com/news/findit-inc-retains-bf-borgers-200000819.html
New Video out on Global Wholehealth Partners. They are increasing their marketing campaign. Check it out and give it a share, like and leave a comment.
Wholesale PPE Supplies COVID-19 Diagnostic Testing Kits Available Online GWHP Corp 877-568-4947
Video provided by Findit.
New Video out on Global Wholehealth Partners. They are increasing their marketing campaign. Check it out and give it a share, like and leave a comment.
Wholesale PPE Supplies COVID-19 Diagnostic Testing Kits Available Online GWHP Corp 877-568-4947
This company is covering EQ they are also covering FDIT. May be a nice play there as well.
TTENTION: Premarket Breakout Alert on:
Equillium Inc. (Nasdaq: EQ) • ElectroCore Inc. (Nasdaq: ECOR)
Dear Fellow Trader,
EQ Is On Immediate ALERT!
Wall Street is Showing Major Interest in EQ!
Clinical Trial Shows Itolizumab Reduces Mortality
in Patients Hospitalized with COVID-19
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon
Biocon has received emergency use approval from Drugs Controller General of India for itolizumab in the treatment of CRS in COVID-19 patients with moderate to severe ARDS
Equillium planning global randomized controlled clinical trial of itolizumab in COVID-19 patients under a U.S. IND
LA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that as reported by its partner, Biocon Limited, a clinical trial conducted in India by Biocon demonstrated that itolizumab significantly reduced mortality in patients hospitalized with COVID-19. Biocon has announced that the Drugs Controller General of India (DCGI), the regulatory agency that oversees drug approvals, has granted restricted emergency use of itolizumab for the treatment of cytokine release syndrome (CRS) in COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) in India.
Based on the encouraging topline results of the study reported by Biocon and subsequent DCGI approval to treat COVID-19 patients, Equillium is planning to conduct a global randomized controlled clinical trial of itolizumab in COVID-19 patients for which it will file a U.S. investigational new drug application (IND).
Biocon conducted a randomized, controlled, open-label study at four hospitals in India, enrolling a total of 30 hospitalized COVID-19 patients with moderate to severe ARDS. Twenty patients were randomized to receive itolizumab plus best supportive care, while 10 patients received best supportive care alone. The primary endpoint was mortality at one month. As reported by Biocon:
• In the itolizumab arm there were no deaths and all patients have recovered; in the control arm three patients died and the remainder have recovered
• The mortality benefit observed in the itolizumab arm was statistically significant
• Consistent with the observed clinical improvement, patients who received itolizumab also experienced significant reductions in inflammatory cytokines such as IL-6 and TNFa
“The results of this clinical trial reported by Biocon are encouraging and support the hypothesis that itolizumab’s novel immune-modulating mechanism may have promise in addressing the severe immuno-inflammatory complications experienced by COVID-19 patients,” said Bruce Steel, co-founder and CEO of Equillium. “We are working with Biocon to review its full dataset with the goal to move swiftly in determining appropriate next steps to accelerate further development of itolizumab to treat moderate to severely ill COVID-19 patients in the U.S. and abroad in the face of this global crisis.”
“The results of this clinical trial reported by Biocon are encouraging and support the hypothesis that itolizumab’s novel immune-modulating mechanism may have promise in addressing the severe immuno-inflammatory complications experienced by COVID-19 patients,” said Bruce Steel, co-founder and CEO of Equillium. “We are working with Biocon to review its full dataset with the goal to move swiftly in determining appropriate next steps to accelerate further development of itolizumab to treat moderate to severely ill COVID-19 patients in the U.S. and abroad in the face of this global crisis.”
“As the entire world grapples with the ongoing COVID-19 pandemic it is critical to identify new treatments that improve outcomes for the sickest patients, and these reported early clinical data suggest that itolizumab holds promise,” said Siddhartha Mukherjee, M.D., Ph.D., a clinical advisor to Equillium and Biocon, Pulitzer Prize Award-winning author, and an Associate Professor of Medicine at Columbia University’s Herbert Irving Comprehensive Cancer Center.
Ivor S. Douglas, M.D., FRCP (UK) Professor of Medicine, Chief of Pulmonary and Critical Care and Medical Director, Medical Intensive Care Denver Health Medical Center, added, “Patients with COVID-19 experience acute respiratory failure caused by the immune system flooding the bloodstream with inflammatory proteins, which can kill tissue, damage organs and pathologically activate clotting cascades in the lungs, heart, and kidneys.
The novel mechanism of itolizumab, which works by inhibiting CD6 to reduce the activation and trafficking of pathogenic T cells that release pro-inflammatory cytokines, may be well suited to address SARS-CoV-2 induced inflammation that drives respiratory failure in patients with COVID-19. The preliminary data as reported by Biocon is encouraging and highlights the urgent importance of further evaluating the potential therapeutic efficacy of itolizumab in treating patients diagnosed with COVID-19.”
Itolizumab is a first-in-class immune-modulating antibody therapeutic with a novel mechanism of action that inhibits the activity and trafficking of pathogenic T cells that release pro-inflammatory cytokines in a range of autoimmune and inflammatory diseases. Equillium acquired rights to develop and commercialize itolizumab in the U.S., Canada, Australia and New Zealand through an exclusive collaboration and license agreement with Biocon.
Equillium is currently evaluating itolizumab under two open U.S. INDs for the treatment of acute graft-versus-host disease and lupus nephritis, as well as conducting a clinical study in uncontrolled asthma in Australia and New Zealand.
Biocon previously developed and received approval of Itolizumab for the treatment of plaque psoriasis in India, demonstrating the product was safe and well tolerated. Biocon manufactures itolizumab at commercial scale at its cGMP bio-manufacturing facility that is regulated by the U.S. Food & Drug Administration.
In March of this year, as a result of the emerging COVID-19 pandemic, Equillium announced that it was pausing enrollment in the EQUIP trial for uncontrolled asthma and the EQUALISE trial for lupus nephritis. Today Equillium announces that patient enrollment in both of these studies has resumed.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need.
Equillium’s initial product candidate, itolizumab, is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically validated therapeutic that has demonstrated a favorable safety and tolerability profile. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Itolizumab is currently marketed in India under the trade name, “ALZUMab” for the treatment of chronic plaque psoriasis and in July 2020 received emergency use approval in India to treat CRS in COVID-19 patients with moderate to severe ARDS. Equillium believes that itolizumab has the potential to be a best-in-class disease modifying therapeutic and is advancing the clinical development of itolizumab in the following severe immuno-inflammatory disorders: uncontrolled asthma, acute graft-versus-host disease, and lupus nephritis.
========================================================================
ECOR Is On Immediate ALERT!
Wall Street is Showing Major Interest in ECOR!
ElectroCore Announces FDA Emergency Use Authorization for use of GammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients
Intended use allows gammaCore Sapphire CV use at home or in a healthcare setting
BASKING RIDGE, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the FDA has issued an Emergency Use Authorization (EUA) authorizing the use of gammaCore Sapphire™ CV non-invasive vagus nerve stimulation (nVNS) at home or in a healthcare setting to acutely treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief.
“Needless to say, we are very pleased to have received this EUA, and we intend work vigorously to make this novel therapy available to physicians treating known or suspected COVID 19 patients who are experiencing exacerbation of asthma-related breathing difficulty,” said Dan Goldberger, Chief Executive Officer of electroCore.
Peter Staats, MD, Chief Medical Officer, went on to say, “Results from prior pilot studies that evaluated gammaCore for the acute treatment of asthma support our belief that nVNS may provide much needed relief to patients who are experiencing asthma-related breathing difficulty, which can be particularly debilitating in patients with COVID-19.”
JP Errico, electroCore Board member, co-founder and co-inventor of gammaCore, commented, “This FDA decision is an encouraging first step toward developing evidence that may provide a basis for electroCore to pursue expansion of nVNS into reactive airway disease (RAD), which was the first area of research for electroCore.”
The trading session is about to begin shortly, so don't delay and pull up it on your trading screen before you miss out on another easy profitable day trading idea scenario.
?Immediately Turn Your Attention To My Focus Stock Findit Inc. (FDIT)
This is my next stock ready to potentially move in a big way, here's why...
FDIT is now displaying the holy grail of bullish breakout signals - GOLDEN CROSS.
Also, on our side is Wall Streets leading provider of market data to the global financial, media, and commodity industries just issued FDIT a bullish 50% BUY Rating Short Term. See here
Technical Analysis:
FDIT is now displaying the holy grail of bullish breakout signals - GOLDEN CROSS.
A golden cross is formed when the 50 day moving average crosses the 200 day moving average, signaling the beginning of a breakout rally.
The medium term (faster) average price of the stock has crossed its long term (slower) average. Look at the chart below, you will see the short-term moving average (blue line) moves up through the long-term moving average (red line).
It's an extremely bullish signal that indicates the beginning of a Breakout Rally!
Check out the chart and you'll see this stock has a history of days where double and even triple digit gains are unleashed.
?FDIT Chart Looks To Be On The Verge Full-On BREAKOUT
The 50 Day MA Just Crossed The 200 Day MA
Signaling Bullish Golden Cross
4 Reasons To Get FDIT On Your Watch-list Right Now
FDIT has Triggered 4 New Bullish Trade Signals
FDIT is experiencing a "Golden Cross"
FDIT has a very small float
My Track Record Speaks For Itself
Multiple Breakout Catalysts Signaling Breakout Potential
With several potential bullish catalysts working in FDIT favor, I believe it could be setting up for its next big potential breakout.
It’s important to note, FDIT is no stranger to explosive breakouts and just like our recent winners, our latest trade idea has a razor thin float and double and even triple-digit gain potential.
In fact, I first initiated coverage on FDIT Monday June 22nd and it broke-out to a high of $.0999, running up 53% from previous close, then we saw some profit-taking set in on Tuesday June 23rd and it retraced, bottoming out at a low of $.0455, before rocketing to a high of $.08 Wednesday June 24th, allowing this ticker to bounce hard creating an awesome swing trade opportunity providing 75% gains from Tuesdays low.
It surged from $.0115 on May 1st to a high of $.086 on June 10th booking over 647% in Gains, virtually overnight.
It surged from a low of $.0151 on Dec 31st, 2019 to a high of $.04 Jan 28th booking over 164% in Gains, virtually overnight.
Then back in Nov of last year it ran from $.03 to a high of $.069 on Nov 15th running up 130% in gains.
Another example was on July 22nd, 2019 it ran from $.023 to a high of $.10 ON Aug 21, 2019 running up 233% in gains.
I hope you are as excited as I am for Monday’s trading action! You don't want to miss it.
As you can see, there are multiple bullish catalysts signaling breakout potential!
So, without wasting any more time, don't delay and pull up FDIT on your trading screen before you miss out on another potential winner, with tremendous upside potential.
Chief Editorial,
PTA Team
This could really help Findit increase membership.
Amazon.com demands TikTok app be removed from employee devices over 'security risks' -memo
https://finance.yahoo.com/news/amazon-com-demands-tiktok-app-170331792.html?.tsrc=fin-notif
Profit Alert: One of Our Previous Picks AIHS
Explodes HIGHER Hitting $2.35 Thursday (Huge Profits)
If you missed it... DO NOT miss ---> FDIT
Pay Close Attention To This Chart: FDIT
Shares Could Potentially Breakout Very Soon...
Dear Fellow Trader,
Yet again my alerts continue to deliver us staggering profits!
For the new members who just joined us, welcome! For our loyal ones, a big Congrats on this weeks picks!
One of my previous picks AIHS continued trending up yesterday hitting $2.35 providing 193% in gains since I first alerted you on it. That’s almost a “triple” your money situation!
I first alerted my members to AIHS on Feb 18th at approx. $.80 premarket. Since then it has trended up to a high of $2.35 yesterday, up 193% from my initial alert.
Yesterday BGFV Rocketed to a high of $3.36 up 75% in Gains from my initial alert premarket at approx. $1.92.
Also yesterday BGI Rocketed to a high of $1.97 running up 51% in Gains!
My pick on Monday ROSEU Rocketed to a premarket high of $1.80 up 200% in Gains from my initial alert. I alerted members to ROSEU Monday July 6th at approx. $.60 premarket, and it rocketed to a premarket high of $1.80 for 200% Gains. That’s a “clean triple” your money situation!
If you liked your previous picks which soared up in price for a "clean double" your money situation, I believe you are going to love... FDIT
Immediately Turn Your Attention To My Focus Stock Findit Inc. (FDIT)
This is my next stock ready to potentially move in a big way, here's why...
FDIT is now displaying the holy grail of bullish breakout signals - GOLDEN CROSS.
Also, on our side is Wall Streets leading provider of market data to the global financial, media, and commodity industries just issued FDIT a bullish 50% BUY Rating Short Term. See here
Technical Analysis:
FDIT is now displaying the holy grail of bullish breakout signals - GOLDEN CROSS.
A golden cross is formed when the 50 day moving average crosses the 200 day moving average, signaling the beginning of a breakout rally.
The medium term (faster) average price of the stock has crossed its long term (slower) average. Look at the chart below, you will see the short-term moving average (blue line) moves up through the long-term moving average (red line).
It's an extremely bullish signal that indicates the beginning of a Breakout Rally!
Check out the chart and you'll see this stock has a history of days where double and even triple digit gains are unleashed.
?FDIT Chart Looks To Be On The Verge Full-On BREAKOUT
The 50 Day MA Just Crossed The 200 Day MA
Signaling Bullish Golden Cross
4 Reasons To Get FDIT On Your Watch-list Right Now
FDIT has Triggered 4 New Bullish Trade Signals
FDIT is experiencing a "Golden Cross"
FDIT has a very small float
My Track Record Speaks For Itself
Multiple Breakout Catalysts Signaling Breakout Potential
With several potential bullish catalysts working in FDIT favor, I believe it could be setting up for its next big potential breakout.
It’s important to note, FDIT is no stranger to explosive breakouts and just like our recent winners, our latest trade idea has a razor thin float and double and even triple-digit gain potential.
In fact, I first initiated coverage on FDIT Monday June 22nd and it broke-out to a high of $.0999, running up 53% from previous close, then we saw some profit-taking set in on Tuesday June 23rd and it retraced, bottoming out at a low of $.0455, before rocketing to a high of $.08 Wednesday June 24th, allowing this ticker to bounce hard creating an awesome swing trade opportunity providing 75% gains from Tuesdays low.
It surged from $.0115 on May 1st to a high of $.086 on June 10th booking over 647% in Gains, virtually overnight.
It surged from a low of $.0151 on Dec 31st, 2019 to a high of $.04 Jan 28th booking over 164% in Gains, virtually overnight.
Then back in Nov of last year it ran from $.03 to a high of $.069 on Nov 15th running up 130% in gains.
Another example was on July 22nd, 2019 it ran from $.023 to a high of $.10 ON Aug 21, 2019 running up 233% in gains.
I hope you are as excited as I am for Monday’s trading action! You don't want to miss it.
As you can see, there are multiple bullish catalysts signaling breakout potential!
So, without wasting any more time, don't delay and pull up FDIT on your trading screen before you miss out on another potential winner, with tremendous upside potential.
Chief Editorial,
PTA Team
Get Stock Alerts
Dear Fellow Trader,
Immediately turn your attention to Findit Inc. (FDIT)
This is my next stock ready to potentially move in a big way, here's why...
FDIT is now displaying the holy grail of bullish breakout signals - GOLDEN CROSS.
Also, on our side is Wall Streets leading provider of market data to the global financial, media, and commodity industries just issued FDIT a bullish 50% BUY Rating Short Term. See here
Technical Analysis:
FDIT is now displaying the holy grail of bullish breakout signals - GOLDEN CROSS.
A golden cross is formed when the 50 day moving average crosses the 200 day moving average, signaling the beginning of a breakout rally.
The medium term (faster) average price of the stock has crossed its long term (slower) average. Look at the chart below, you will see the short-term moving average (blue line) moves up through the long-term moving average (red line).
It's an extremely bullish signal that indicates the beginning of a Breakout Rally!
Check out the chart and you'll see this stock has a history of days where double and even triple digit gains are unleashed.
FDIT Chart Looks To Be On The Verge Full-On BREAKOUT
The 50 Day MA Just Crossed The 200 Day MA
?Signaling Bullish Golden Cross
4 Reasons To Get FDIT On Your Watch-list Right Now
FDIT has Triggered 4 New Bullish Trade Signals
FDIT is experiencing a "Golden Cross"
FDIT has a very small float
My Track Record Speaks For Itself
Multiple Breakout Catalysts Signaling Breakout Potential
With several potential bullish catalysts working in FDIT favor, I believe it could be setting up for its next big potential breakout.
It’s important to note, FDIT is no stranger to explosive breakouts and just like our recent winners, our latest trade idea has a razor thin float and double and even triple-digit gain potential.
In fact, it surged from $.0115 on May 1st to a high of $.086 on June 10th booking over 647% in Gains, virtually overnight.
It surged from a low of $.0151 on Dec 31st, 2019 to a high of $.04 Jan 28th booking over 164% in Gains, virtually overnight.
Then back in Nov of last year it ran from $.03 to a high of $.069 on Nov 15th running up 130% in gains.
Another example was on July 22nd, 2019 it ran from $.023 to a high of $.10 ON Aug 21, 2019 running up 233% in gains.
I hope you are as excited as I am for Monday’s trading action! You don't want to miss it.
As you can see, there are multiple bullish catalysts signaling breakout potential!
So, without wasting any more time, don't delay and pull up FDIT on your trading screen before you miss out on another potential winner, with tremendous upside potential.
Yours for greater profits,
?Editor In Chief, GetStockAlerts Team
https://getstockalerts.com/
FDIT is one tenth of a penny away from the 50 day and 200 day average crossing. Known as the Golden Cross.
https://stockcharts.com/h-sc/ui?s=fdit
I see this board has 3 moderators. The red letter on top seem to have been placed their by a moderator. As a moderator having accurate information in the areas moderators control would be helpful. I have reviewed the flings on OTC Markets and he has not sold shares in literally multiple years.
He in fact converted shares from common for preferred. That being the facts the statement above until something is filed is inaccurate.
Would one or 3 of the moderators remove this being it is misleading to people.
UBID Reestaurant.com featured on Findit. This is good to see they are doing some online marketing. I wonder how many shareholders are aware that UBID acquired Restaurant.com?
They are starting to get information out there.
https://news.findit.com/news/1812185/enjoy-great-deals-at-local-restaurants-with-the-best-food-deal-certificates
https://finance.yahoo.com/news/findit-features-members-restaurant-com-195500099.html
In barely over one month we have seen more volume on FDIT from June 4th of 2019 to June 4th of 2020.
June 4th 2019 to June 4th 2020
Trades = 1,577
Volume= 13,793,966
$Volume $540,417.00
Average Volume per trade 8,746
June 5th 2020 to July 1 2020
Trades = 1626
Volume = 14,786,491
$Volume = $862,443.00
Average Volume per trade 9,093 shares
This is one full year above to a little over 1 month.
Golden Cross is 2/10th of a penny from forming at or around 0.034.Currently the 50 day average is 0.032 - 200 day average is 0.034. With the recent coverage that has been limited and only started on the 19th of June FDIT is being looked at more in the last month than it possibly has in the past 5 plus years.
https://stockcharts.com/h-sc/ui?s=fdit
When the Golden Cross forms would you prefer to be in before it or after?
Traders please let us know your thoughts. Will day traders get an alert once it forms?
If holders stay long it will be pretty difficult to not see a run, if this volume keeps up.
Looks like the demand for testing may increase
https://www.yahoo.com/gma/arkansas-governor-calls-trump-invoke-defense-production-act-160029201--abc-news-topstories.html
Big Campaign on this one. Lots of emails over the past 3 days.
Sign up and get all of these updates if you want at https://www.otctipreporter.com/
Mydecine Drops Bombshell Acquisition News Their Acquiring Mindleap
Health’s Advanced Digital Telehealth Platform
Dear Fellow Trader,
Immediately turn your attention to Mydecine Innovations Group (MYCOF)
MYCOF is my next stock that looks ready to move in a major way, so make sure you have it pulled up on your trading screen Monday morning at the opening bell!
Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions.
Mydecine experienced cross functional teams have the capabilities to oversee all areas of drug development including synthesis, drug delivery system development, clinical trial execution, through to product commercialization and marketing.
By leveraging strategic partnerships with scientific, medical, military, and clinical organizations Mydecine is at the forefront of the efficient development of psychedelic derived medicines and therapeutic solutions.
Their trailblazing portfolio of companies is focused on providing innovative and effective treatment options that can help millions of people live healthier lives.
Mydecine Signs Partnership Agreement With
Applied Pharmaceutical Innovation
Mydecine Innovations Group Inc. announced the establishment of a research division agreement with Applied Pharmaceutical Innovation (“API”), a translational commercial drug development institute hosted in the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences.
The agreement with API provides exceptional capacity for Mydecine and the ability to significantly speed their product development with leading experts in the pharmaceutical sciences and established drug development facilities.
The Faculty of Pharmacy and Pharmaceutical Sciences is consistently ranked in the top 15 globally for the citations of research by international QS rankings in pharmacy and pharmacology and includes a wide range of experts from discovery, pharmaceutical analysis, drug action, disposition, formulation and clinical development.
Mydecine is also able to access broader expertise through the agreement such as API’s collaborating institute the Alberta Machine Intelligence Institute (Amii) – ranked among the top 5 institutes in the world for AI/ML – as well as experts in mycology, pharmacometrics, neuropharmacology and much more at universities throughout the API network.
Through the agreement, Mydecine has the ability to immediately commence fungal discovery investigations with varietal mushrooms and their extracts, including scheduled substances.
With access to GMP capacity and Health Canada licenses that include the ability to move to import and export, conduct R&D, and clinical trials Mydecine is able to begin work that will take other companies years to establish the capability for. Research and development is commencing with a significant program to extract, analyze, and determine the effects of various compounds from fungi and their pharmacokinetic disposition and development of dosage forms for specific indications, providing Mydecine with an extensive assets and capacity to become a leader in the space. The end goal is developing products with clinical applications over a period of three years.
“We see this agreement as a core component of our work as a company,” says Mydedine CEO Josh Bartch “the API team at the Faculty of Pharmacy and Pharmaceutical Sciences gives us the ability to rocket our product development ahead by years, providing the know-how, facilities, and licenses to quickly establish Mydecine as a leader in naturally sourced therapies for a wide variety of indications. The research division also provides a phenomenal synergy with our other recent acquisitions, giving us a dedicated team to explore myco-inspired treatments particularly for areas of high need such as mental health.”
“Our partnership with the University of Alberta will unlock brand new avenues for the study of medical uses of mushrooms,” Robert Roscow, CSO of Mydecine. “This partnership is a fundamental aspect of Mydecine’s expanding unique research network. We are investigating the potential of mushrooms and their compounds to improve human health and wellness.
This research partnership opens up, not only investigation of single molecules from mushrooms but also more complex formulations. The breadth of research resources at the University of Alberta, from world class AI to cultivation and pharmacology, as well as their possession of Health Canada License allows an unprecedented level of study.”
“Back to the fungal future,” Dr. Neal Davies, Dean, Faculty of Pharmacy and Pharmaceutical Sciences “Pharmaceutical activity of fungal metabolites have been known for at least 15 centuries and contemporary research has discovered some novel molecule leads for unique mycological medications for nature inspired treatments in the new millennium. This bodes very well for the program developing promising treatments.”
“We’re thrilled to be working with Mydecine,” says API CEO, Andrew MacIsaac, “we see their focus as one of growing importance and high potential that will serve them well. By developing a world class R&D program that discovers potential new lead compounds, synergistic effects, and increased therapeutic indications for mushroom-derived products, Mydecine will stand out in this bourgeoning sector.
Mydecine Drops Bombshell Acquisition News Their Acquiring Mindleap
Health’s Advanced Digital Telehealth Platform
MYCOF Just Released Blockbuster Acquisition News They Have Signed a Definitive agreement with Mindleap Health Inc. (“Mindleap”) for the acquisition of a 100% interest in MindLeap’s Digital Telehealth Platform focused on the emerging psychedelics industry.
Mindleap Health we are focused on positively impacting society through a disruptive platform for psychedelic aftercare and by developing new forms of medicine.
Advanced Digital Telehealth Platform Technology
Mindleap is a digital health platform that helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind. Online mental healthcare brings convenience, improves access to treatments and can lead to more personal breakthroughs. Mindleap’s proprietary platform is designed by clinical psychologists and neuroscientists to provide professional support and personalized treatment for every person.
?The Mindleap platform will provide support for people that are looking to achieve personal transformations and overcome mental health challenges. Mindleap is the only digital health platform that combines telehealth with mood, emotion and habit tracking.
Mental health has been a big issue and is a major focus for the Mydecine Group of companies. Currently the World Health Organization estimates that there are more than 450 million people suffer from mental health disorders worldwide placing mental disorders among the leading causes of ill-health and disability worldwide. The US has the highest prevalence of mental health disorders in the world with 27 percent of adults, yet only 41 percent of the people who had a mental disorder in the past year received professional health care or other mental health services due to convenience and cost associated.
Mydecine Director and CEO, Josh Bartch, stated: "This acquisition brings Mydecine an elite team drawn from tech, mental health, and science, paired with innovative technology with a strong USP and large addressable market. The scalability of the platform means high potential return on investment especially given Mindleap's 1st mover advantage in the rapidly emerging psychedelic medicine sector."
Mindleap is focused on making a considerable difference in people's lives by improving access to mental health services and providing more personalized and effective treatments utilizing the latest technology. The Mindleap Platform upon launch will provide:
Convenient and more affordable access to mental health services
Psychedelic aftercare, addiction, and holistic wellness services
On Demand access to mental health programs
Automated appointment booking and international payments
Secure and confidential video sessions
Critical tools for improved outcomes and personalized care
Easy to use software with fast learning curve for specialists
Secured encrypted system that is HIPAA and GDPR compliant
High engagement features and gamification that improve user experience
The team of mental health professionals that led the product design at Mindleap comprise of four PHD's including leading neuroscientists, psychotherapists, and clinical psychologists.
Mindleap's CTO Simon Abou-Antoun has 10+ years of technical leadership, managing large projects and developing custom solutions for companies including Amazon, Scotia Bank and Fiat Chrysler. Simon commented: "We have gathered a strong team with different sets of skills ranging from software developers, UX/UI designers and IOS and Android experts. Our full stack, frontend, backend, Cloud and QA specialists are currently focused on ensuring all requirements are met so we can launch Mindleap by the end of summer."
Mindleap's founder and CEO Nikolai Vassev brings a unique skillset to the company as he has proven experience driving top line software licensing and SAAS revenue into some of the largest organizations in the world. During his career he has sold millions of dollars worth of cybersecurity and data analytics solutions and understands the intricacies of successfully implementing software solutions that are bringing value to customers, partners, and end users.
Nikolai Vassev, Mindleap Founder and CEO commented: "The intense anxiety and fear that many people are feeling has led to social instabilities as the virus crisis and economic collapse continues to worsen and compound already existing problems. Mindleap's platform is set to launch in a few short months and will provide much needed support to those people suffering from depression, addiction and other mental health issues."
About Mydecine Innovations Group
Mydecine Innovation's Group is a life sciences company focused on the development and commercialization of products and services that contribute to improving overall health and wellbeing. The company's mission is to create a healthier world through advanced technologies, natural products, and psychedelic derived medicines. Mydecine Innovations Group owns a group of trailblazing companies that are focused on helping millions of people live better lives and our portfolio includes:
Cannabis & Fungi Based Products
Mycology Research & Development
Disruptive Technology
Therapeutic Treatment Facilities
Large-Scale Distribution
Psychedelic-Derived Medicines
About Mindleap Health
Mindleap Health is developing an advanced digital telehealth platform that will provide support for people that are looking to achieve personal transformations and overcome mental health challenges. MindLeap is the only digital telehealth platform that combines telemedicine with mood, emotion, and habit tracking. This is a paradigm shift to conventional mental health as Mindleap personalized support and users have the tools needed to track their progress and take control of their mental health.
Mindleap Health is at the forefront of this industry with its digital telehealth platform focused on the psychedelic therapy industry. Mindleap has recognized that there is an unmet need for people to access psychedelic integration specialists and is creating the world’s first platform focusing on psychedelic aftercare.
The tools Mindleap is building are the first of their kind to allow the patient to monitor, record, and track their mood and habits (both positive and negative) along with providing access to modern health services, namely integrated coaching to translate psychedelic experiences into positive change.
The system is completely secure and compliant with HIPAA and GDPR mandates and is being developed by a world-class development team with a proven track record.
Finally, Digital Mental Healthcare
As a society, we are becoming more familiar with digital healthcare. Electronic medical records are now the norm. The Covid-19 pandemic has resulted in more usage of video visits to doctors as people sheltered in place to prevent virus spread. A crisis being a catalyst is certainly unfortunate, but it did just make e-visits more mainstream as doctors and patients alike embraced social distancing.
Apropos, already valued at $31.46BIL in 2018, the global telemedicine market is expected to grow at a 19.3% rate by 2025, indicating that adoption is only going to keep accelerating.
Mindleap's comprehensive platform, expected to launch at the end of summer, includes video visits, appointment scheduling and payment solutions.
Mindleap is also capitalizing on the world’s love of digital technologies, such as smartphones and connected wearable devices, in a newer science dubbed digital phenotyping. By passively collecting data (e.g. sleep patterns, exercise, social patterns), outcomes can be predicted using Artificial Intelligence and Machine Learning. This information subsequently helps healthcare providers optimize support.
It is the epitome of the purpose of Big Data to anonymously help the greater cause by aggregating massive amounts of info. It’s very valuable from both financial and humanitarian perspectives.
The market opportunity as a first mover is tremendous, to say the least. There are more than 577,000 mental health professionals and over 13,000 behavioral health clinics in the U.S. to treat the more than 45 MIL Americans that have a mental illness.
To put this market opportunity into perspective, consider Livongo. The company has made a splash on Wall Street ($7.4BIL market cap) with an application connecting diabetics to physicians with the strategy that better engagement will promote better health. There are fewer diabetics (~34 MIL) in the U.S. than people with mental illness.
We’re at a Tipping Point
Thankfully, awareness is growing about the very real medicinal usefulness of psilocybin and other psychedelics. Indeed, they remain illegal as Schedule I drugs currently, but positions are beginning to soften to encourage clinical research. Oakland and Denver have already decriminalized magic mushrooms and over 100 other cities are considering similar action.
Leading research organizations, including Johns Hopkins, have dedicated millions of dollars to study psychedelics, which will only help create tailwinds with every positive development.
The next logical progression is providing patients with the best support possible to help them achieve meaningful changes to their quality of life. That’s exactly what Mindleap Health – and now Mydecine Innovations Group – is bringing to the table by changing the shape of the aftercare model.
Big Names are Investing in Psychedelics (Should You?)
If you’re still on the fence about psychedelics, however, you need to know that there are some very big names in the business. Some, like cannabis guru Bruce Linton, see the same early regulatory signs and support that medicinal cannabis received. Others, like Canadian businessman Kevin O’Leary, are investing in psychedelics after passing on cannabis completely.
Both Linton and O’Leary recently became heavy investors in Mind Medicine Inc., a private Canadian neuro-pharmaceutical company aiming to develop drugs with the same mental health benefits but without the associated high. They’re joined by James Bailey, a partner at the private equity firm Bail Capital that has invested heavily in the industry.
Another name that should be familiar to investors is Peter Thiel, the Silicon Valley billionaire that co-founded PayPal and sits on the board for Facebook Inc. Thiel is a heavy investor in psychedelics. He’s joined in the venture by investing in a German biotech start-up with a lot of venture capital support looking to fund more research on psilocybin, MDMA, and other psychedelic drugs.
A major driving force in the psychedelics wave isn’t a name, however, it’s a government organization. The US Food and Drug Administration (FDA) has been impressively receptive to psychedelics in recent years, starting in 2017 when it granted Breakthrough Therapy Designation to MDMA-assisted psychotherapy. Since then it has expanded the number of companies allowed to research the drugs, and in March of this year granted approval for a ketamine-related depression drug from Johnson & Johnson.
Leading research organizations, including Johns Hopkins, have dedicated millions of dollars to study psychedelics, which will only help create tailwinds with every positive development.
As the emerging sector sees more trials and investments, you can expect more big names to enter the psychedelics playing field. With cannabis acting as a roadmap and helping to shift public opinion towards previously illicit drugs, and with a pure medicinal focus helping propel the industry, it’s looking like psychedelics are the real deal!
Science based sustainable craft mushroom cultivation and genetic IP research and development
Farms aims to be a pioneer in the cultivation and genetic IP development of mushrooms and Fungi. The Company is comprised of scientific and horticulture experts that have years of experience in the isolation of compounds, genetic composition development, large scale horticulture and IP and patent formulation.
?The Company will cultivate a variety of strains of mushroom and fungi that will be used as ingredients in the research and development of revolutionary products and IP. Additionally, the Company will develop new and improved strains, genetics and methodology to vastly improve the efficiency of mycology cultivation as it currently exists.
Creating functional products for the future
Mydecine Wellness is a revolutionary product developer and manufacturer of a variety of proprietary formulated nutraceutical and supplemental products based on the use of various strains of mushrooms and fungi.
The Company will leverage its science, research, product development and marketing expertise to utilize the vast benefits of various compounds found within certain strains of mushroom and fungi found throughout the world.
Unlocking the vast medical potential of psychedelics through public and private research and development
Mydecine Labs will be a trailblazer in the research, development and discovery of groundbreaking IP derived from psychedelic compounds, namely psilocybin, found in various strains of mushroom and fungi. The Company intends to have a two-prong approach both public and private, leveraging its extensive science team as well as partnerships with pertinent departments of major universities.
The Bottom Line...
The Barchart Technical Opinion Rating Upgraded
MYCOF Bullish 100% BUY Opinion
Wall Streets leading provider of market data to the global financial, media, and commodity industries just issued MYCOF a bullish 100% BUY Rating Medium Term.
I strongly suggest you click here and read the technicals immediately to learn why MYCOF could turn out to be another potential breakout gainer like my previous low float winners.
It’s important to remember that historically, small-cap biotech, life sciences, nutraceutical and therapeutics companies have been our biggest winners that are cut from the same cloth as MYCOF.
I am urging all of our subscribers to add MYCOF to the top of their watch list right now, and be ready Monday morning at the opening bell!
BullRally
Trading Research Team[url][/url][tag]insert-text-here[/tag]
Getting substantial coverage over the weekend from various newsletters. This one came over this morning.
Mydecine Drops Bombshell Acquisition News Their Acquiring Mindleap
Health’s Advanced Digital Telehealth Platform
Dear Fellow Trader,
Immediately turn your attention to Mydecine Innovations Group (MYCOF)
MYCOF is my next stock that looks ready to move in a major way, so make sure you have it pulled up on your trading screen Monday morning at the opening bell!
Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions.
Mydecine experienced cross functional teams have the capabilities to oversee all areas of drug development including synthesis, drug delivery system development, clinical trial execution, through to product commercialization and marketing.
By leveraging strategic partnerships with scientific, medical, military, and clinical organizations Mydecine is at the forefront of the efficient development of psychedelic derived medicines and therapeutic solutions.
Their trailblazing portfolio of companies is focused on providing innovative and effective treatment options that can help millions of people live healthier lives.
Mydecine Signs Partnership Agreement With
Applied Pharmaceutical Innovation
Mydecine Innovations Group Inc. announced the establishment of a research division agreement with Applied Pharmaceutical Innovation (“API”), a translational commercial drug development institute hosted in the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences.
The agreement with API provides exceptional capacity for Mydecine and the ability to significantly speed their product development with leading experts in the pharmaceutical sciences and established drug development facilities.
The Faculty of Pharmacy and Pharmaceutical Sciences is consistently ranked in the top 15 globally for the citations of research by international QS rankings in pharmacy and pharmacology and includes a wide range of experts from discovery, pharmaceutical analysis, drug action, disposition, formulation and clinical development.
Mydecine is also able to access broader expertise through the agreement such as API’s collaborating institute the Alberta Machine Intelligence Institute (Amii) – ranked among the top 5 institutes in the world for AI/ML – as well as experts in mycology, pharmacometrics, neuropharmacology and much more at universities throughout the API network.
Through the agreement, Mydecine has the ability to immediately commence fungal discovery investigations with varietal mushrooms and their extracts, including scheduled substances.
With access to GMP capacity and Health Canada licenses that include the ability to move to import and export, conduct R&D, and clinical trials Mydecine is able to begin work that will take other companies years to establish the capability for. Research and development is commencing with a significant program to extract, analyze, and determine the effects of various compounds from fungi and their pharmacokinetic disposition and development of dosage forms for specific indications, providing Mydecine with an extensive assets and capacity to become a leader in the space. The end goal is developing products with clinical applications over a period of three years.
“We see this agreement as a core component of our work as a company,” says Mydedine CEO Josh Bartch “the API team at the Faculty of Pharmacy and Pharmaceutical Sciences gives us the ability to rocket our product development ahead by years, providing the know-how, facilities, and licenses to quickly establish Mydecine as a leader in naturally sourced therapies for a wide variety of indications. The research division also provides a phenomenal synergy with our other recent acquisitions, giving us a dedicated team to explore myco-inspired treatments particularly for areas of high need such as mental health.”
“Our partnership with the University of Alberta will unlock brand new avenues for the study of medical uses of mushrooms,” Robert Roscow, CSO of Mydecine. “This partnership is a fundamental aspect of Mydecine’s expanding unique research network. We are investigating the potential of mushrooms and their compounds to improve human health and wellness.
This research partnership opens up, not only investigation of single molecules from mushrooms but also more complex formulations. The breadth of research resources at the University of Alberta, from world class AI to cultivation and pharmacology, as well as their possession of Health Canada License allows an unprecedented level of study.”
“Back to the fungal future,” Dr. Neal Davies, Dean, Faculty of Pharmacy and Pharmaceutical Sciences “Pharmaceutical activity of fungal metabolites have been known for at least 15 centuries and contemporary research has discovered some novel molecule leads for unique mycological medications for nature inspired treatments in the new millennium. This bodes very well for the program developing promising treatments.”
“We’re thrilled to be working with Mydecine,” says API CEO, Andrew MacIsaac, “we see their focus as one of growing importance and high potential that will serve them well. By developing a world class R&D program that discovers potential new lead compounds, synergistic effects, and increased therapeutic indications for mushroom-derived products, Mydecine will stand out in this bourgeoning sector.
Mydecine Drops Bombshell Acquisition News Their Acquiring Mindleap
Health’s Advanced Digital Telehealth Platform
MYCOF Just Released Blockbuster Acquisition News They Have Signed a Definitive agreement with Mindleap Health Inc. (“Mindleap”) for the acquisition of a 100% interest in MindLeap’s Digital Telehealth Platform focused on the emerging psychedelics industry.
Mindleap Health we are focused on positively impacting society through a disruptive platform for psychedelic aftercare and by developing new forms of medicine.
Advanced Digital Telehealth Platform Technology
Mindleap is a digital health platform that helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind. Online mental healthcare brings convenience, improves access to treatments and can lead to more personal breakthroughs. Mindleap’s proprietary platform is designed by clinical psychologists and neuroscientists to provide professional support and personalized treatment for every person.
The Mindleap platform will provide support for people that are looking to achieve personal transformations and overcome mental health challenges. Mindleap is the only digital health platform that combines telehealth with mood, emotion and habit tracking.
Mental health has been a big issue and is a major focus for the Mydecine Group of companies. Currently the World Health Organization estimates that there are more than 450 million people suffer from mental health disorders worldwide placing mental disorders among the leading causes of ill-health and disability worldwide. The US has the highest prevalence of mental health disorders in the world with 27 percent of adults, yet only 41 percent of the people who had a mental disorder in the past year received professional health care or other mental health services due to convenience and cost associated.
Mydecine Director and CEO, Josh Bartch, stated: "This acquisition brings Mydecine an elite team drawn from tech, mental health, and science, paired with innovative technology with a strong USP and large addressable market. The scalability of the platform means high potential return on investment especially given Mindleap's 1st mover advantage in the rapidly emerging psychedelic medicine sector."
Mindleap is focused on making a considerable difference in people's lives by improving access to mental health services and providing more personalized and effective treatments utilizing the latest technology. The Mindleap Platform upon launch will provide:
Convenient and more affordable access to mental health services
Psychedelic aftercare, addiction, and holistic wellness services
On Demand access to mental health programs
Automated appointment booking and international payments
Secure and confidential video sessions
Critical tools for improved outcomes and personalized care
Easy to use software with fast learning curve for specialists
Secured encrypted system that is HIPAA and GDPR compliant
High engagement features and gamification that improve user experience
The team of mental health professionals that led the product design at Mindleap comprise of four PHD's including leading neuroscientists, psychotherapists, and clinical psychologists.
Mindleap's CTO Simon Abou-Antoun has 10+ years of technical leadership, managing large projects and developing custom solutions for companies including Amazon, Scotia Bank and Fiat Chrysler. Simon commented: "We have gathered a strong team with different sets of skills ranging from software developers, UX/UI designers and IOS and Android experts. Our full stack, frontend, backend, Cloud and QA specialists are currently focused on ensuring all requirements are met so we can launch Mindleap by the end of summer."
Mindleap's founder and CEO Nikolai Vassev brings a unique skillset to the company as he has proven experience driving top line software licensing and SAAS revenue into some of the largest organizations in the world. During his career he has sold millions of dollars worth of cybersecurity and data analytics solutions and understands the intricacies of successfully implementing software solutions that are bringing value to customers, partners, and end users.
Nikolai Vassev, Mindleap Founder and CEO commented: "The intense anxiety and fear that many people are feeling has led to social instabilities as the virus crisis and economic collapse continues to worsen and compound already existing problems. Mindleap's platform is set to launch in a few short months and will provide much needed support to those people suffering from depression, addiction and other mental health issues."
About Mydecine Innovations Group
Mydecine Innovation's Group is a life sciences company focused on the development and commercialization of products and services that contribute to improving overall health and wellbeing. The company's mission is to create a healthier world through advanced technologies, natural products, and psychedelic derived medicines. Mydecine Innovations Group owns a group of trailblazing companies that are focused on helping millions of people live better lives and our portfolio includes:
Cannabis & Fungi Based Products
Mycology Research & Development
Disruptive Technology
Therapeutic Treatment Facilities
Large-Scale Distribution
Psychedelic-Derived Medicines
About Mindleap Health
Mindleap Health is developing an advanced digital telehealth platform that will provide support for people that are looking to achieve personal transformations and overcome mental health challenges. MindLeap is the only digital telehealth platform that combines telemedicine with mood, emotion, and habit tracking. This is a paradigm shift to conventional mental health as Mindleap personalized support and users have the tools needed to track their progress and take control of their mental health.
Mindleap Health is at the forefront of this industry with its digital telehealth platform focused on the psychedelic therapy industry. Mindleap has recognized that there is an unmet need for people to access psychedelic integration specialists and is creating the world’s first platform focusing on psychedelic aftercare.
The tools Mindleap is building are the first of their kind to allow the patient to monitor, record, and track their mood and habits (both positive and negative) along with providing access to modern health services, namely integrated coaching to translate psychedelic experiences into positive change.
The system is completely secure and compliant with HIPAA and GDPR mandates and is being developed by a world-class development team with a proven track record.
Finally, Digital Mental Healthcare
As a society, we are becoming more familiar with digital healthcare. Electronic medical records are now the norm. The Covid-19 pandemic has resulted in more usage of video visits to doctors as people sheltered in place to prevent virus spread. A crisis being a catalyst is certainly unfortunate, but it did just make e-visits more mainstream as doctors and patients alike embraced social distancing.
Apropos, already valued at $31.46BIL in 2018, the global telemedicine market is expected to grow at a 19.3% rate by 2025, indicating that adoption is only going to keep accelerating.
Mindleap's comprehensive platform, expected to launch at the end of summer, includes video visits, appointment scheduling and payment solutions.
Mindleap is also capitalizing on the world’s love of digital technologies, such as smartphones and connected wearable devices, in a newer science dubbed digital phenotyping. By passively collecting data (e.g. sleep patterns, exercise, social patterns), outcomes can be predicted using Artificial Intelligence and Machine Learning. This information subsequently helps healthcare providers optimize support.
It is the epitome of the purpose of Big Data to anonymously help the greater cause by aggregating massive amounts of info. It’s very valuable from both financial and humanitarian perspectives.
The market opportunity as a first mover is tremendous, to say the least. There are more than 577,000 mental health professionals and over 13,000 behavioral health clinics in the U.S. to treat the more than 45 MIL Americans that have a mental illness.
To put this market opportunity into perspective, consider Livongo. The company has made a splash on Wall Street ($7.4BIL market cap) with an application connecting diabetics to physicians with the strategy that better engagement will promote better health. There are fewer diabetics (~34 MIL) in the U.S. than people with mental illness.
We’re at a Tipping Point
Thankfully, awareness is growing about the very real medicinal usefulness of psilocybin and other psychedelics. Indeed, they remain illegal as Schedule I drugs currently, but positions are beginning to soften to encourage clinical research. Oakland and Denver have already decriminalized magic mushrooms and over 100 other cities are considering similar action.
Leading research organizations, including Johns Hopkins, have dedicated millions of dollars to study psychedelics, which will only help create tailwinds with every positive development.
The next logical progression is providing patients with the best support possible to help them achieve meaningful changes to their quality of life. That’s exactly what Mindleap Health – and now Mydecine Innovations Group – is bringing to the table by changing the shape of the aftercare model.
Big Names are Investing in Psychedelics (Should You?)
If you’re still on the fence about psychedelics, however, you need to know that there are some very big names in the business. Some, like cannabis guru Bruce Linton, see the same early regulatory signs and support that medicinal cannabis received. Others, like Canadian businessman Kevin O’Leary, are investing in psychedelics after passing on cannabis completely.
Both Linton and O’Leary recently became heavy investors in Mind Medicine Inc., a private Canadian neuro-pharmaceutical company aiming to develop drugs with the same mental health benefits but without the associated high. They’re joined by James Bailey, a partner at the private equity firm Bail Capital that has invested heavily in the industry.
Another name that should be familiar to investors is Peter Thiel, the Silicon Valley billionaire that co-founded PayPal and sits on the board for Facebook Inc. Thiel is a heavy investor in psychedelics. He’s joined in the venture by investing in a German biotech start-up with a lot of venture capital support looking to fund more research on psilocybin, MDMA, and other psychedelic drugs.
A major driving force in the psychedelics wave isn’t a name, however, it’s a government organization. The US Food and Drug Administration (FDA) has been impressively receptive to psychedelics in recent years, starting in 2017 when it granted Breakthrough Therapy Designation to MDMA-assisted psychotherapy. Since then it has expanded the number of companies allowed to research the drugs, and in March of this year granted approval for a ketamine-related depression drug from Johnson & Johnson.
Leading research organizations, including Johns Hopkins, have dedicated millions of dollars to study psychedelics, which will only help create tailwinds with every positive development.
As the emerging sector sees more trials and investments, you can expect more big names to enter the psychedelics playing field. With cannabis acting as a roadmap and helping to shift public opinion towards previously illicit drugs, and with a pure medicinal focus helping propel the industry, it’s looking like psychedelics are the real deal!
Science based sustainable craft mushroom cultivation and genetic IP research and development
Farms aims to be a pioneer in the cultivation and genetic IP development of mushrooms and Fungi. The Company is comprised of scientific and horticulture experts that have years of experience in the isolation of compounds, genetic composition development, large scale horticulture and IP and patent formulation.
The Company will cultivate a variety of strains of mushroom and fungi that will be used as ingredients in the research and development of revolutionary products and IP. Additionally, the Company will develop new and improved strains, genetics and methodology to vastly improve the efficiency of mycology cultivation as it currently exists.
Creating functional products for the future
Mydecine Wellness is a revolutionary product developer and manufacturer of a variety of proprietary formulated nutraceutical and supplemental products based on the use of various strains of mushrooms and fungi.
?The Company will leverage its science, research, product development and marketing expertise to utilize the vast benefits of various compounds found within certain strains of mushroom and fungi found throughout the world.
Unlocking the vast medical potential of psychedelics through public and private research and development
Mydecine Labs will be a trailblazer in the research, development and discovery of groundbreaking IP derived from psychedelic compounds, namely psilocybin, found in various strains of mushroom and fungi.
?The Company intends to have a two-prong approach both public and private, leveraging its extensive science team as well as partnerships with pertinent departments of major universities.
The Bottom Line...
The Barchart Technical Opinion Rating Upgraded
MYCOF Bullish 100% BUY Opinion
Wall Streets leading provider of market data to the global financial, media, and commodity industries just issued MYCOF a bullish 100% BUY Rating Medium Term.
I strongly suggest you click here and read the technicals immediately to learn why MYCOF could turn out to be another potential breakout gainer like my previous low float winners.
It’s important to remember that historically, small-cap biotech, life sciences, nutraceutical and therapeutics companies have been our biggest winners that are cut from the same cloth as MYCOF.
I am urging all of our subscribers to add MYCOF to the top of their watch list right now, and be ready Monday morning at the opening bell!
Happy Trading!!
?Your StockEgg Editor
For those of you who may not know OTC TIP REPORTER was one of if not the first to cover Co-Diagnostics CODX, back in the beginning of 2020.
Got the email last night that OTC Tip Reporter is covering Findit (FDIT) and Mydecine Stock Symbol MYCOF. These 2 FDIT and MYCOF will be worth watching. The email for MYCOF came out Friday-yesterday after the close.
Here is a snippet of it.
MYCOF Drops Bombshell News: Mydecine Signs Definitive Agreement to Acquire Mindleap Health’s Advanced Digital Telehealth Platform
Dear Fellow Trader,
Immediately turn your attention to Mydecine Innovations Group (MYCOF)
MYCOF is my next stock that looks ready to move in a major way, so make sure you have it pulled up on your trading screen Monday morning at the opening bell!
https://www.otctipreporter.com/
OTC TIP REPORTER IS COVERING Mydecine Innovations Group Inc.
https://www.findit.com/otctipreporter/RightNow/mycof-is-my-next-stockthat-looks-ready-to-move-in-a/5484552a-dffe-4f78-81d7-0621ec0ffc02?httproute=True
Be sure to follow the link below to sign up for our newsletter to stay up to date on Mydecine Farms and other innovative companies.
https://www.otctipreporter.com/
Here are some Previous Picks covered by OTC Tip Reporter
• (SRNE): Profile Price Pre-Mkt $4.30 5/15 – High $10.00 5/18 (130% Gains)
• (XRF): Profile Price Pre-Mkt $1.40 5/6 – High $3.06 (118% Gains)
• (AXSM): Profile Price Pre-Mkt $5.00 1/07/19 – High $109.52 4/27/20 (2,090% Gains)
• (APDN): Profile Price Pre-Mkt $4.80 4/15 – High $16.39 5/14 (2,090% Gains)
• (CIRX): Profile Price $.045 4/16 – High $.20 (344% Gains)
• (BLPH): Profile Price Pre-Mkt $5.50 2/18 – High $26.00 3/20 (372% Gains)
June 4th through yesterday 6,007,118 showing short. As long as the holders let this continue to build even more ideally to the amount held in DTC it will more than likely payoff. If you keep selling into the shorts you are doing exactly what they want you to do.
https://otcshortreport.com/company/FDIT
The volume since June 5th on FDIT picked up quite a bit. Take the volume over the past 11 trading days from June 5th to June 20th the total volume was approx. 9 million plus shares. Compare that for the previous 12 months from June 4th 2019 to June 4th 2020 to total volume was approx. 13 million shares. Only 4 million shares more over a 50 week period versus 2 weeks.
The message above in red is factually incorrect and is quite easy to verify by looking at Findit's filings. Firth has not sold any shares in years. In fact a vast majority of the holdings by Firth and insiders has been voluntarily converted from preferred to common a few years back and remains locked up.
With that being filed and made public through OTC Markets and press releases the header of this board is very misleading, well beyond misleading it is false.
I have watched this board and heard that the moderator has deleted messages when he or she decides to, even when the messages are not incorrect. I truly hope this post is left for the readers who may not do certain due diligence.
The reduction in common shares over the years to common and the cancellation of other shares 3,650,000 the company is not diluting shareholders down or selling insider stock and can't with the lock up other than 1% a quarter or a percentage of the volume. With many firms not even taking in shares that trade down here and the DTC shares of record it does not look like any insiders are selling any shares. I've seen other people on the board claiming they have millions of shares and if they do, they could be sellers.
If they are and they have been in it as long as they have been it would have been foolish to hold this long with the company finally getting coverage. Their is a report out on https://walletinvestor.com/stock-forecast/fdit-stock-prediction this came out a couple of weeks ago and may be part of the reason for the influx of trading. Read the report, they predict FDIT over $4.00. The report has no disclaimer and from what I hear the company did not know about this until after it was published.
I have reviewed the IR firm that was recently hired and looked at their track record this year and it has been pretty stellar. I did see a few companies that did trade a lot of volume and it surely looked like the insiders or holders were dumping into the volume. While the others performed very well.
Here are a few over the past 6 months.
CODX was trading under a $1.00 at the end of 2019. It closed on Friday at $17.24 on 3,177,040 shares. When coverage began from the same firm as WAFU and the FDIT took on recently the shares were at around $1.13. Coverage began and volume went from 91,100 shares one day to 36,063,100 shares the next. The stock did not move much the first day which was odd. Or maybe not maybe the traders got caught off guard and traded it while sellers came in with the new found volume but as time went on and not much time the stock traded up from $1.13 on Jan. 9th to $15.96 close on Feb 27th. And like I wrote earlier closed at $17.24 yesterday.
WAFU So this one covered about 2 weeks ago. June 9th was at $2.13 on 27,500 volume day of coverage traded up to $15.39 closed at $7.15 on 65,019,500 shares. These are verifiable number not an opinion. On Friday the stock closed at $6.02 up approx. 300% from 9 days earlier when the coverage began.
SPONF received coverage last Monday and volume increased from 1,145,730 to 6,227,798 and did not see an increase in share price it's possible that insiders and / or shareholders sold into the volume.
Findit we will see. With the insiders shares converted from common to preferred and their number of shares they have owned has not decreased in years, verifiable it does not seem like they are selling. If they are we will know in about 60 days when the filings for the 2nd quarter are due.
The real test will be for the shareholders that have been in the stock as they are now enjoying the fruits of their patience. Will they allow the fruits to grow and get ripe or will they spoil their own upside with trading theories that probably ought not be practiced until Findit has its S1 filed and funding in place to continue to build their business.
They talk about the Golden Cross, predictions of $4.00 or more other companies seeing sellers in 2 deals while other deals from the same PR/IR had tremendous success in the past few weeks and months.
Findit is not a big company and may never be but it looks like an opportunity with hope and with management that has been focused on building out Findit.com over the years and the app and now a new version is coming. The site does what it is set up to do. The App has some things it can do to improve but it too does what it is built to do and it does it well. How many times do you have an opportunity to find a company that has stuck to its plan over the years and is not seeing some coverage from WalletInvestor and some other people coming onto this board and posting.
These next few years will be something we will look back on regardless if you own shares in FDIT and sell into the buying how will you look back on it. Best decision or worst decision. Even if you sell at a profit if you sale much lower than it goes to you know in your mind you lost money. I wonder what would happen if over the next few months the holders remained that holders and let the calendar tick away and see is WalletInvestor correct will FDIT hit their target of $4.539 USD? We will find out one way or another.